William W. O'Neill, MD, FACC

Dr. William W. O'Neill is an internationally renowned interventional cardiologist and a pioneer of structural heart disease therapy in the United States. He performed the first transcatheter aortic valve replacement (TAVR) in the U.S. and has spent more than four decades advancing minimally invasive cardiovascular care.

Dr. O'Neill currently serves as Medical Director of the Center for Structural Heart Disease at Henry Ford Hospital in Detroit and as Chief Medical Officer at Amavita Research. He has served as National Principal Investigator on multiple pivotal trials for the FDA, including the Edwards PARTNER, Protect II, and Protect IV studies, and is the founder of the National Cardiogenic Shock Initiative — a multi-center quality improvement program that established the modern standard of care for AMI cardiogenic shock.

He has authored or co-authored more than 400 peer-reviewed publications and has trained generations of interventional cardiologists. At Amavita Research he provides scientific oversight, protocol design input, and senior PI leadership across the active cardiovascular trial portfolio.